Nurix Therapeutics (NRIX) announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least a BTK inhibitor and a BCL-2 inhibitor. To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Nurix Therapeutics initiated with a Buy at UBS
- Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright
- Nurix Therapeutics Appoints Anil Kapur to Board
- Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com